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Abstract  
The endothelial glycocalyx (eGlx) constitutes the first barrier to protein in all blood vessels. 
This is particularly noteworthy in the renal glomerulus, an ultrafiltration barrier. Leakage of 
protein, such as albumin, across glomerular capillaries results in albumin in the urine 
(albuminuria). This is a hall mark of kidney disease and can reflect loss of blood vessel integrity 
in microvascular beds elsewhere. We discuss evidence demonstrating that targeted damage to 
the glomerular eGlx results in increased glomerular albumin permeability. EGlx is lost in 
diabetes and experimental models demonstrate loss from glomerular endothelial cells. Vascular 
endothelial growth factor (VEGF)A is upregulated in early diabetes, which is associated with 
albuminuria. Treatment with paracrine growth factors such as VEGFC, VEGF165b and 
angiopoietin-1 can modify VEGFA signalling, rescue albumin permeability and restore 
glomerular eGlx in models of diabetes. Manipulation of VEGF receptor 2 signalling, or a 
common eGlx biosynthesis pathway by these growth factors, may protect and restore the eGlx 
layer. This would help to direct future therapeutics in diabetic nephropathy. 
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1. List of abbreviations 
Ang-1       Angiopoietin-1 
A disintegrin and metalloproteinase domain 17 ADAM17 
Chondroitin sulphate      CS 
eGLX       Endothelial glycocalyx 
Endoplasmic reticulum    ER 
Endothelial surface layer     ESL 
GAG        Glycosaminoglycans 
Glomerular endothelial cells     (GEnC) 
Glomerular basement membrane   GBM 
Glomerular filtration barrier     GFB 
Glomerular filtration rate    GFR 
Hyaluronidase      HYAL 
Hyaluronic acid      HA 
Hyaluronic acid synthase     HAS 
Heparanase       HPSE 
Heparan sulphate      HS 
Hydroxyethylstarch      HES  
Matrix metalloproteinase     MMP 
Munich Wistar Frompter     MWF 
Urine albumin creatinine ratios    uACR 
Vascular endothelial growth factor    VEGF 
Vascular endothelial growth factor receptor   VEGFR 
Wheat germ agglutinin     WGA  
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2. Review overview 
The focus of this review is to examine how components of the endothelial glycocalyx (eGlx) 
influence vascular permeability, particularly in the diabetic glomerulus, and the role they may 
have as a potential therapeutic target in diabetic nephropathy. First an overview of the eGlx 
will be given, followed by evidence demonstrating its importance in vascular permeability in 
health, diabetes and diabetic nephropathy. Finally, this review will present approaches that 
restore glomerular eGlx through common pathways, thereby highlighting therapeutic potential.  
3. Endothelial glycocalyx (eGlx) 
The eGlx is a complex carbohydrate meshwork, present on the luminal surface of blood vessels. 
It is primarily composed of glycoproteins (not a focus of this review) and proteoglycans, which 
have a protein core, embedded into the endothelial cell surface. Glycoprotein cores are attached 
to acidic oligosaccharides and terminal sialic acids, while proteoglycan cores are attached to 
multiple, long, unbranched glycosaminoglycan (GAG) chains [1]. The eGlx is often referred 
to as an extended endothelial surface layer (ESL) to incorporate the structural contribution of 
absorbed plasma proteins. It is a dynamic structure [2], with a high turnover rate, that is greatly 
influenced by surrounding factors.  
Proteoglycan synthesis begins when ribosomes, bound to the endoplasmic reticulum (ER), 
synthesise a protein core backbone and feed it into the ER lumen. From here it is transported 
to the lumen of the Golgi apparatus where a serine residue of the core protein is attached to a 
tetrasaccharide via an O-glycosidic bond [3]. GAG chains are then extended from the non-
reducing end by glycosyltransferase enzymes that alternately attach an amino and an acidic 
sugar [4-6]. The main core proteins found in the eGlx are transmembrane syndecans and 
membrane-bound glypicans [7], while the three main GAG are heparan sulphate (HS) 
chondroitin sulphate (CS) and hyaluronic acid (hyaluronan, HA). During polymerisation, GAG 
can be modified by sulfation (the addition of a sulfate group to an individual monosaccharide), 
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which is what gives the eGlx an overall negative charge. GAG can also be modified by de-
acetylation (removal of an acetyl group from a monosaccharide) and/or epimerisation (the 
alteration of a monosaccharide at one stereochemical position only e.g. in the transformation 
of glucuronic acid to iduronic acid) [8]. GAG distribution on core proteins is highly variable. 
For example, endothelial syndecans-1, -2 and -4 exhibit three GAG attachment sites, which 
predominantly bind HS. However, syndecan-1 has two additional sites specifically for 
chondroitin sulphate [9]. HA is a unique GAG as it is not sulphated, is unbranched, and is not 
linked to a core protein. It is the largest GAG with repeating disaccharide units reaching in 
excess of 106 Da [5]. These lengths are achievable as it is not constrained by the Golgi space 
during chain extension. It is synthesised at the inner surface of the plasma membrane by 
hyaluronic acid synthases (HAS1, HAS2 and HAS 3) [10].  
4. Contribution of eGlx to microvascular permeability 
Vascular permeability is the movement of water and molecules across the capillary wall and 
was originally modelled on Starling principles [11]; 
(Jv/A) = Lp[(Pc – Pi) – σ (Πp – Πi)] 
Where: Jv/A is the volume filtered per unit area, Lp is the hydraulic conductance, Pc is the 
capillary hydrostatic pressure, Pi is the interstitial hydrostatic pressure, σ is the osmotic 
reflection co‐efficient, Πp is the oncotic pressure on plasma-side of endothelial surface layer 
and Πi is the oncotic pressure in the interstium. However, recently these principles have been 
revised. It is now recognised that there is no steady state fluid absorption in capillaries [12]; Πp 
cannot draw fluid back into capillaries (although it can reduce flow from capillaries) and Πi 
has no effect as a filtration force [13]. This is because the eGlx exerts an oncotic force (Πg), 
caused by the plasma proteins in the ESL, that regulates filtration of water at the EnC surface 
[65]. There is also a protein free zone below the GAG chains of the eGlx and above the 
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endothelial cells, the sub eGlx space. This acts as a buffer zone to oncotic forces. Thus, Πi is 
replaced by Πg in the revised Starling’s principles as follows;  
(Jv/A) = Lp[(Pc – Pi) – σ (Πp – Πg)] [12]Experimental models demonstrate that eGlx damage 
leads to vascular complications [14]. For example, in isolated coronary arterioles the movement 
of fluorescently labelled albumin into the surrounding bath was used to demonstrate that 
pronase (which removes the eGlx) increased albumin permeability 2.3-fold [15]. Pronase was 
also used to show that, when perfused into individually cannulated frog mesenteric vessels, 
eGlx depth was reduced and hydraulic conductivity (water and small solute permeability) was 
increased without impacting tight junctions [16]. Notably, restoration of eGlx depth in these 
vessels recovered hydraulic conductivity. Similarly, we demonstrated that  neuraminidase 
removed eGlx in perfused, single cannulated, frog mesenteric vessels, resulting in increased 
albumin permeability [17].  Of note, in isolated perfused guinea pig hearts, eGlx degradation 
by heparinase I led to increased extravasation of albumin and hydroxyethylstarch (HES), yet 
not small solutes. The authors confirmed that under “normal” conditions there was low 
filtration from venules; under hypoalbuminuric conditions (i.e. no colloid perfusion) the 
increased (colloid free) extravasate occurred independently of eGlx; but when eGlx was 
damaged in the presence of colloid, more colloid rich extravasation occurred. Interestingly, 
extravasation was less with albumin vs HES, despite the fact that the albumin had a lower 
colloidal pressure than HES. It is thought that albumin seals the damaged eGlx [18], thereby 
restoring the ESL. Accordingly, these authors have further modified Starling’s principles as 
follows; 
 (Jv/A) = Lp[(Pc – Pi) – σ (Πe – Πg)] 
Where Πe=colloid osmotic pressure within the ESL and Πg= colloid osmotic pressure directly 
below it. [18] 
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Vascular leakage and oedema are important concerns post-surgery with those experiencing 
perioperative ischemia (e.g. due to aortic clamping or cardiopulmonary by-pass). The 
importance of eGlx in vascular leakage in these patients was highlighted for the first time by 
Rehm et al. [19]. SDC1 and HS were measured in arterial blood of patients before, during and 
after vascular surgery. Both SDC1 and HS shedding were increased after different operative 
procedures in association with conditions of reperfusion (but not due to surgery itself) [19]. 
Using a complementary animal model of ischemia reperfusion, the authors confirmed that 
increased SDC1 and HS shedding were seen in association with reduced coronary 
microvascular eGlx depth, by electron microscopy, in guinea pig hearts.  
5. Diabetes and eGlx 
The eGlx has been shown to be altered in a number of pathological situations including 
ischemia-reperfusion injury and inflammation [20-22], hyperglycaemia [23], in chronic kidney 
disease [24]. and during the progression of  diabetes [25, 26]. Diabetes is a major health concern 
worldwide. In the UK between 2015-2016, diabetes-related drugs made up to 10.6% of 
prescribed drugs used in primary care and 6.4% of individuals going to their GPs aged 17yr 
and over were diagnosed with diabetes [27]. In general, diabetic patients suffer ill health, and 
there is strong correlation between diabetes and cardiovascular diseases [28, 29]. More 
specifically, many of those with diabetes will suffer from complications associated with 
microvascular damage, which include retinopathy, neuropathy and nephropathy (collectively 
known as microangiopathy).  
5.2 Diabetes and albuminuria 
Diabetic nephropathy is the main cause of end stage renal failure in the western world [30]. It 
is considered a relatively late complication of diabetes, progressively occurring in susceptible 
patients 15-25yr after the initial onset of diabetes [31, 32]. Albuminuria is correlated with the 
progression of diabetic nephropathy [33] and can be categorised as normoalbuminuric (less 
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than 30mg/day), microalbuminuric (30-300mg/day) or macroalbuminuria (300+mg/day). It is 
also associated with endothelial dysfunction, decline in glomerular filtration rate (GFR) and 
increased risk of cardiovascular disease [34, 35]. Of note, increased GFR also predisposes those 
with diabetes to the development of diabetic nephropathy [36]. Interestingly, even 
normoalbuminuria at the top end of the physiological range is an independent risk factor for 
cardiovascular disease in an otherwise health population [37-39].  
4.2 Diabetes and eGlx dysfunction 
Damage to the eGlx has been shown to occur in both Type-I and Type-II diabetes. Nieuwdorp 
et.al analysed the depth of the eGlx in patients with Type-I diabetes by imaging the erythrocyte-
endothelium gap in sublingual microcirculation using side-stream darkfield imaging, before 
and after leukocyte passage [40]. Using this method, they demonstrated that; eGlx volume was 
reduced in Type-I diabetics; was exacerbated in those diabetics with microalbuminuria; and 
was correlated with increased blood plasma levels of HA and hyaluronidase (which cleaves 
HA). Indeed, in hyaluronidase knock out mice, the development of Type I diabetes-associated 
albuminuria was prevented [41]. EGlx volume has also been shown to be reduced in patients 
with Type-II diabetes in both the sublingual and retinal vascular beds. This was analysed using 
side-stream darkfield imaging and measuring the intravascular distribution of two fluorescent 
tracers of different sizes [26]. 
In addition to hyaluronidase, other enzymes have been implicated in GAG shedding in diabetes. 
For example, circulating matrix metalloproteinases (MMP) 2 and 9, known to cleave 
components of the eGlx [42], were significantly increased in Type I diabetic patients [43]. We 
suggest that TNF-α, an inflammatory mediator in the diabetic milieu, induces MMP-9 
activation, leading to HS cleavage from Sydecan-4 in glomerular endothelial cells [44]. Also, 
vascular endothelial growth factor (VEGF)A which is upregulated in the diabetic milieu 
(discussed in more detail below), can induce glomerular MMP9 expression [45]. Further to 
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this, we have shown that, in an experimental model of albuminuria with glomerular eGlx 
dysfunction, MMP 2/9 inhibition restored glomerular eGlx and prevented albuminuria [46]. 
Another enzyme involved in GAG shedding in diabetes is heparanase (HPSE). Active HPSE 
degrades HS and is upregulated during diabetes in humans and in animal models [47-49]. 
Increased HPSE levels have also been demonstrated in the urine and plasma from Type II 
diabetic patients, and were found to positively correlate with increased glucose levels [48]. An 
increase in vascular permeability is also seen in mice that overexpress heparanase [50] and this 
enzyme has been further linked to the pathophysiology of childhood steroid-sensitive nephrotic 
syndrome [51].  
Hyperglycaemia, an important mediator of the diabetic milieu in Type I and II diabetes, is 
thought to impact eGlx health.  Nieuwdorp et.al showed that acute induction of hyperglycaemia 
in healthy individuals reduced eGlx volume within 6 hours [52]. In culture, hyperglycaemia 
inhibits synthesis of sulphated and non-sulphated GAG, with no demonstrable change in 
proteoglycan expression [53]. Together, these studies demonstrate that eGlx damage is strongly 
associated with the development of albuminuria in diabetes, indeed, the eGlx has been 
proposed as the site of initial damage leading to microalbuminuria [54]. Therefore, the eGlx 
may be a promising target to reduce albuminuria and protect against other microvascular 
complications.  
6. Glomerular eGlx 
Understanding how the glomerulus regulates filtration and maintains selective (restricted) 
protein passage is key to understanding the development and progression of renal pathologies 
in which this restriction is lost, such as in diabetic nephropathy. Blood is filtered across the 
glomerular capillary through a highly specialised filtration barrier. This multi-layered structure 
prevents large proteins, such as albumin, from leaving the blood whilst allowing minimally 
restricted movement of water and small solutes. Traditionally the glomerular filtration barrier 
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(GFB) is presented as a three-layer structure consisting of podocytes (epithelial cells), the 
glomerular basement membrane (GBM) and fenestrated glomerular endothelial cells (GEnC) 
[55]. However, the glomerular eGlx, highlighted in figure 1, has also been shown to 
significantly contribute towards the GFB [56]. Tissue culture studies show that GEnC 
synthesise and express HS [57], CS and HA [58]. CS and HA can be seen within human 
glomeruli in figure 2. In the glomerulus, HS has been identified not only in the eGlx but also 
in the GBM where it is one of the 4 main components along with laminin, collagen IV and 
nidogen. Here it is primarily found as part of the proteoglycan, agrin [59, 60]. Whether GBM 
HS plays a role in protein restriction is under debate [59, 61-63], although a general note for 
these and all Glx studies is that there is a need to discriminate between GAG of eGlx and 
elsewhere (i.e GBM, podocytes and mesangial cells). 
6.1 EGlx and glomerular permeability 
The glomerular eGlx has been suggested to restrict both solutes and fluid (not just large, 
charged proteins) according to a mathematical simulation of the GFB [64]. Its contribution to 
water permeability was confirmed experimentally when a bolus of hyaluronidase or heparinase, 
given in vivo for up to an hour, led to an increase in GFR [65]. EGlx damage in experimental 
models of diabetes was associated with increased glomerular hydraulic conductivity (a measure 
of single nephron GFR). Further, treatment that restored eGlx depth also rescued hydraulic 
conductivity [66]. In cultured human GEnC, targeted eGlx removal led to an increase in trans-
endothelial electrical resistance, indicating increased water and solute flux [57, 58]. 
Various studies have highlighted the importance of eGlx in glomerular large solute (i.e. 
albumin) permeability. For example, glomerular eGlx removal, by hypertonic saline in rats, 
caused an increase in fractional albumin clearance by 12-fold [67]. Additionally, both  
hyaluronidase and chondroitinase individually increased the fractional clearance of albumin in 
isolated, perfused, mouse kidneys ex vivo (although not in vivo) [65, 68]. This was associated 
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with reduced glomerular eGlx depth, although measurements were indirect. However, it is 
worth noting that chondroitinase and hyaluronidase can digest HA and CS respectively, albeit 
at a slower rate [69, 70]. Hyaluronidase given over 4wk in mice reduced glomerular eGlx 
coverage and caused an increase in albumin passage across the GFB (but not urinary albumin 
creatinine ratio (uACR)) [71]. This was determined by anti-albumin immunogold staining in 
the GFB. We have recently shown that a low dose combination of hyaluronidase and 
chondroitinase, given acutely (30min) or chronically (over 2wk), reduced eGlx coverage 
without off-target effects [72, 73]. Under the same conditions we directly measured changes in 
glomerular albumin permeability, which was significantly increased following enzyme 
treatment. By measuring glomerular albumin permeability directly, we could bypass tubular 
reabsorption of albumin which impacts on the sensitivity of uACR measurements [72]. In vitro, 
low dose, targeted enzymatic removal of CS, HS, and HA on cultured GEnC (quantified by 
immunofluorescence) demonstrated that removal of CS and HS, but not HA, increased albumin 
passage across GEnC monolayers [57, 58]. These treatments demonstrate that specific removal 
of eGlx leads directly to a rapid and sustained increase in glomerular albumin permeability. 
Other non-enzyme-based studies have also demonstrated how the eGlx contributes towards 
GFB function. Aged Munich-Wistar Frömter (MWF) rats with spontaneous proteinuric kidney 
disease have decreased eGlx and increased glomerular albumin permeability [74]. 
Additionally, intravenous administration and subsequent absorption of wheat germ agglutinin 
(WGA) lectin decreased glomerular albumin permeability in aged rats, indicating that 
modifications to the eGlx can improve glomerular function [74]. Genetic deletion of the linker 
between HS chains and perlecan (a core protein) caused mice to become proteinuric [75]. We 
have recently shown that aldosterone, in combination with high salt, damages glomerular eGlx 
in vivo, leading to an increased glomerular sieving coefficient of albumin [46]. This follows 
from interesting work by Oberleithner et al on salt overload and eGlx stiffness. Atomic force 
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microscopy studies demonstrated that salt overload increased eGlx stiffness and reduced eGlx 
depth in cultured endothelial cells in an aldosterone dependent manner [76], a potential 
mechanism for  increased sodium accumulation in the tissues. These experiments highlight the 
importance of the eGlx in preventing excess protein passage. 
7. EGlx restoration and diabetic nephropathy  
The key question is; how can we restore eGlx? Significant progress has been made in directly 
targeting the eGlx in diabetic patients. Sulodexide, a mixture of low-molecular weight GAG 
(heparan (80%) and dermatan sulfate (20%)), has been used to treat microvascular 
complications in diabetic patients [77]. Initially, several small scale clinical studies 
demonstrated successful, therapeutic use of Sulodexide, showing an increase in sublingual 
eGlx depth (using side-stream darkfield imaging), a decrease in albuminuria (most effective in 
those with microalbuminuria), and slowed progression of diabetic nephropathy [26, 78]. 
Unfortunately, two larger randomized double-blinded placebo control studies later 
demonstrated that treatment with Sulodexide did not reduce albuminuria, therefore the need 
for a new and effective treatment remains [77, 79]. However, it should be noted that many 
consider the effects of Sulodexide to have been undervalued in these later studies [80-83]. 
Overall, these data suggest that the eGlx may be amenable to therapeutic intervention in 
diabetes and that targeting this structure could prove the key for treating this disease. 
Experimentally, restoration of the eGlx has been demonstrated to be achievable and effective 
in blood vessels outside of the kidney in the coronary [84], pulmonary [85] and mesenteric 
microcirculation [16]. We have also demonstrated  that the eGlx can be restored in glomeruli 
[46, 66, 86] which will be key in targeting albuminuria.  
8.1 Glomerular vascular endothelial growth factors (VEGF) 
Podocyte-GEnC crosstalk is critical to maintain normal glomerular function. Growth factors 
form a major part of this communication, but during disease states, these can become 
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imbalanced. One example of these is the VEGF family of proteins. In humans there are five 
VEGF variants, VEGF-A, -B, -C, -D and placenta growth factor [87]. These proteins each have 
distinct biological roles and are important in blood and lymph vessel formation and vascular 
homeostasis. Alternative splicing of the 8 exon, 7 intron VEGF-A gene gives rise to a number 
of mature isoforms with different biological activities. Of these, VEGF165 is the most 
commonly found variant throughout the body [88, 89]. VEGF165 is important for GEnC 
fenestration formation and health via its main signalling receptor, VEGF receptor 2 
(VEGFR2)[90-92]. However, transgenic overexpression of VEGF165 can cause increased GFR 
in the short term, followed by loss of GFR in the long term [93]. In addition, podocyte-specific 
overexpression of VEGF165 was shown to induce albuminuria, increase glomerular VEGFR2 
phosphorylation and increase glomerular MMP-9 expression [45]. Additionally, VEGF165 has 
also been shown to be upregulated in early diabetic nephropathy in human disease [94, 95] and 
in experimental models [96-99]. VEGFR2 was also shown to be upregulated in early 
experimental diabetic nephropathy and was associated with increased GEnC VEGF165-
VEGFR2 signalling [96]. This has been shown to cause loss of permselectivity and albuminuria 
[100]. Of note, VEGF165 may also induce eGlx loss. As well as promoting glomerular MMP9 
expression [45], it also promoted ADAM17 (another member of the MMP family of proteins) 
activation in cultured human GEnC [58]. Furthermore, VEGF165 has been shown to increase 
shedding of sulphated GAG in cultured human GEnC [58]. In the following section, paracrine 
growth factors will be described that may counterbalance the detrimental effects of glomerular 
VEGF165 to protect from albuminuria in diabetes. We suggest they may act by antagonising 
VEGF165/VEGFR2 signalling to restore the glomerular eGlx. Of course, VEGF165 signalling is 
just one mediator of diabetic nephropathy. As well as counterbalancing the effects of the VEGF 
axis, we believe the end point of these paracrine growth factors, restoring eGlx, would go some 
way to counteract the generic effects of the diabetic milieu. 
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8.2 Podocyte paracrine growth factors  
i. VEGF165b: In 2002, Bates and colleagues described a novel family of VEGFA isoforms, 
where the last 6 amino acids differ due to alternative splicing of exon 8, such that the terminal 
end of exon 8 is transcribed instead of the proximal end. These are depicted as VEGFxxxb. For 
example, VEGF165b has been shown to bind VEGFR2 with the same affinity as VEGF165 [101]. 
Podocyte-specific VEGF165b expression in mice has been shown to block the increase in 
glomerular hydraulic conductivity induced by VEGF165 [102]. Reduced glomerular hydraulic 
conductivity has also been demonstrated in glomeruli isolated from diabetic mice, rats and 
humans treated ex vivo with VEGF165b [66]. Further, in a mouse model of Type I diabetes, 
podocyte-specific expression of VEGF165b significantly reduced albuminuria [66]. This was 
also achieved when a dual insult of VEGF165 overexpression was induced alongside the 
induction of diabetes, supporting the hypothesis that VEGF165b reduces albuminuria through 
antagonising VEGF165. Recombinant human VEGF165b protected against albuminuria in a 
Type II model of diabetes, but only when administered before the development of albuminuria. 
Thus, VEGF165b appears to have an impact on water/small solute and large solute permeability 
in the GFB. The protective effects of VEGF165b on glomerular hydraulic conductivity in 
diabetic rats was shown to be VEGFR2 dependent [66]. The activation of VEGFR2 by 
VEGF165b appears to be endothelial cell-type dependent. In human umbilical vein (large vessel) 
endothelial cells, VEGF165b could bind, but not phosphorylate, VEGFR2 yet in human 
microvascular endothelial cells it resulted in the phosphorylation of Akt [101]. Of note, 
overexpression of VEGF165b in glomeruli caused increased VEGFR2 expression and 
phosphorylation in both healthy and diabetic mouse glomeruli [66]. This suggests that 
VEGF165b could have differential VEGFR2 signalling effects in different vascular beds. 
Critically, VEGF165b has also been shown to modify the eGlx. This was demonstrated in an 
early model of Type I diabetes in mice where human recombinant VEGF165b administration 
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restored glomerular eGlx depth. This may be via delayed downstream signalling by VEGF165b-
induced activation of VEGFR2, potentially involving a role for VEGFR2/VEGFR1 
heterodimer formation [103]. 
ii. Ang1: Angiopoietins are a family of endothelial cell growth factors, with essential roles in 
regulating vascular growth, development and maturation. The complex interaction between the 
angiopoietins and vascular endothelial growth factors determine endothelial cell behaviour, 
therefore they are key players in microvascular permeability, both in health and diabetic 
nephropathy [104-107]. The two major members of the angiopoietin family are angiopoietin-1 
(Ang1) and angiopoietin-2 (Ang2) [108]. Tie2 is the main signalling receptor and binds both 
Ang1 and Ang2, although in most circumstances only Ang1 induces receptor phosphorylation 
[109-111]. Ang2 predominantly antagonises Ang1-induced phosphorylation of Tie2 [110]. 
Tie2 together with VEGFR2 activation is required for endothelial cell survival and vessel 
stabilization [92, 112, 113]. In healthy mice, Ang1 reduced the vascular leakage of 70kDa 
macromolecules from newly formed mouse blood vessels [114] and from mature vessels 
(mouse and human) following treatment with permeabilising reagents [115, 116]. Moreover, 
Ang1 reduced hydraulic conductivity in rat glomeruli and in continuous frog mesenteric vessels 
[16]. The reflection coefficient (a measure of macromolecular restriction) in continuous vessels 
was also increased. Critically, Ang1 increased eGlx depth in continuous vessels. All these data 
indicate that Ang1 decreased vascular water and solute permeability, potentially via eGlx. 
Therefore, we hypothesised that Ang1 could modify glomerular eGlx to restrict albuminuria.  
Of note, Ang-2 reduced eGlx depth in human umbilical vein endothelial cells in a heparanase 
dependent manner, which was blocked by Ang-1 [117]. Further, in an in vivo model, Ang-2 
was shown to increase vascular leak which was blocked by heparanase inhibition [117]. In 
diabetes the balance between Ang1 and Ang-2 is lost, which also impacts on VEGF165. Ang2 
mRNA was upregulated in human diabetic glomeruli and Ang1 was significantly decreased in 
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a Type 1 diabetic mouse model [104]. In these mice, when Ang1 was overexpressed by 
podocytes, albuminuria was reduced and Tie2 phosphorylation was increased, highlighting the 
protective effects of Ang1 in diabetes. Of note, in the diabetic mice, glomerular VEGFA 
expression was increased and glomerular VEGFR2 expression was decreased, but VEGFR2 
phosphorylation was increased. Notably, podocyte-specific overexpression of Ang1 
significantly reduced the increased VEGFR2 phosphorylation [104]. Also, kidney cortex 
soluble VEGFR1 expression was increased, which can sequester VEGFA. Therefore, the 
effects of Ang1 may be two-pronged; Tie2 activation and VEGF165 signalling suppression.  
Our group investigated if the protective capabilities of Ang1 in diabetes may be mediated by 
the eGlx. First, we confirmed that Ang1 (given ex vivo) significantly reduced albumin 
permeability in glomeruli isolated from Type 1 diabetic rats [72]. We then demonstrated that 
recombinant Ang1, given i.v. 30min before sacrifice, significantly restored glomerular eGlx in 
diabetic animals, shown by quantitative electron microscopy. This suggests that Ang1 effects 
glomerular function through glomerular eGlx [72]. 
iii. VEGFC: VEGFC is most commonly associated with developmental lymphangiogenesis, 
where it is required for normal development of the endothelial lymphatic system, signalling 
through VEGFR3 [118]. It also signals through VEGFR3 to maintain the differentiated 
lymphatic endothelium in adults [119]. Like VEGFA, VEGFC can signal to vascular 
endothelial cells, increasing migration and proliferation by stimulating VEGFR2 [120]. 
Binding to VEGFR2 by VEGFC occurs at the same binding site as VEGF165, as indicated by 
the ability of each growth factor to displace the other [120]. In the glomerulus, VEGFC is 
expressed by podocytes and acts on GEnC [121]. Unusually, we could not demonstrate 
phosphorylation of VEGFR3 by VEGFC in cultured human GEnCs, but could show 
phosphorylation of VEGFR2, albeit over a longer time course than VEGFA (30min v.s. 2min) 
[121]. We examined phosphorylation of VEGFR2 tyrosine residues by VEGFC, however we 
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did not find significant phosphorylation at Tyr 951, 1175 or 1214; sites involved in VEGF165 
activation and downstream signalling (Figure 3). This suggests that VEGFR2 phosphorylation 
is delayed and perhaps total phosphorylation is reduced in GEnC by VEGFC. In these cells 
VEGFC reduced macromolecular protein passage [121]. We suggest that this is due to the 
synthesis of unsulfated and sulphated GAG by VEGFC (discussed in more detail below) [122]. 
Using our glomerular albumin permeability assay, we demonstrated that ex vivo treatment of 
isolated mouse glomeruli with VEGFC blocked the increased permeability induced by 
VEGF165. In addition, VEGFC could rescue raised glomerular albumin permeability in 
glomeruli isolated from Type II diabetic (and albuminuric) mice [73]. We have also 
demonstrated that the effects induced by VEGFC, like the other protective growth factors 
discussed, may be mediated via the eGlx. Glomerular albumin permeability was increased in 
mice administered GAG enzymes, both acutely (30min) and chronically (2wk), but VEGFC 
blocked this effect whilst restoring eGlx depth and/or coverage [73].  
We went on to investigate the effect of VEGFC on albuminuria and eGlx in vivo using 
podocyte-specific overexpression of VEGFC. Of note, VEGFC reduced glomerular VEGFA 
mRNA expression and had no long term detrimental effects on glomerular function [73], in 
contrast to that described for podocyte-specific overexpression of VEGFA [45]. Glomerular 
VEGFR2/VEGFR3 heterodimer formation was significantly increased in podocyte-specific 
VEGFC overexpressing mice [73]. This suggests that VEGFC may antagonise VEGF165 
signalling by competitively binding VEGFR2, but may induce differential signalling through 
modification by VEGFR3. We confirmed that podocyte-specific overexpression of VEGFC 
could rescue albuminuria in a Type I diabetic mouse model, if it was expressed before 
albuminuria developed [73]. Increased glomerular VEGFR2 expression in diabetic mice was 
significantly reduced by VEGFC, supporting our hypothesis that VEGFC antagonises 
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VEGF165/VEGFR2 signalling. Together, this data suggests that VEGFC protects from 
albuminuria through modification of VEGFR2 signalling and eGlx restoration. 
8. A common pathway for therapeutic targeting of eGlx?  
VEGF165b, Ang1 and VEGFC all protect from increased glomerular VEGF165 signalling and 
from albuminuria in diabetes, preferentially when administered during early development. 
Critically, these growth factors counterbalance VEGFA signalling, either through 
expression/sequestering of VEGF165 and/or potential modification of VEGFR2 signalling. 
Blockade of the glomerular VEGF165 system in disease needs to be moderate to avoid 
additional glomerular dysfunction [92, 123-125]. Perhaps counterbalancing by these important 
endogenous mediators provides the key. In addition, restoration of the glomerular eGlx by these 
growth factors was associated with reduced glomerular small solute (VEGF165b and Ang1) and 
albumin permeability (VEGF165b, Ang1, VEGFC). We know that VEGF165b restores 
glomerular eGlx and that this leads to increased WGA lectin binding [66]. WGA binds N-
acetyl glucosamine, a component of HS and HA, and N-acetyl neuraminic acid, which is a 
major sialic acid. This gives some clues as to the components of the VEGF165b-restored eGlx. 
More extensive investigations have been carried out for Ang1 and VEGFC. Ang1 can 
restore/enhance eGlx in frog mesentery vessels and glomerular capillaries in vivo within 30min. 
Whether this is due to de novo synthesis or not has yet to be proven, but inhibition of vesicle 
translocation by Brefeldin A blocked the effect, indicating that restoration may come from pre-
existing pools of GAG [16]. In human microvascular endothelial cells in vitro, Ang1 increased 
sulphated GAG content of cell supernatant [16]. GAG were also shown to be effected by Ang-
1 in cultured human GEnC, where treatment induced de novo synthesis of both sulphated and 
un-sulphated GAG, as determined by 3H glucosamine and liquid chromatography, within 1hr 
(Desideri et al, unpublished). These experiments suggest that rapid de novo synthesis in vivo is 
a plausible explanation. Using the same technique, de novo GAG synthesis was also seen in 
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GEnC in response to VEGFC after 24hr [58]. 76% of sulphated GAG synthesised by VEGFC 
were highly sulphated, compared to only 32% under control conditions. Additionally, using 
immunofluorescence, VEGFC was shown to induce HA and CS synthesis. Furthermore, 
VEGFC significantly increased NDST2 mRNA, a sulfotransferase, which supports 
observations of increased eGlx charge. As mentioned previously, these effects by VEGFC are 
in contrast to VEGF165, which may promote GAG shedding [45, 58]. This leads to a complex 
interaction between these families of growth factors, VEGF165/VEGFR2 signalling and eGlx 
modifications as summarised in figure 4.  
In conclusion, there are similarities arsing in the mechanism of protection of these paracrine 
growth factors. The next step is to identify the common pathways influenced by these growth 
factors that promote restoration of glomerular eGlx, and those that protect from degradation. 
This will prove to be a powerful, multi-targeted approach to albuminuric diabetic nephropathy. 
In addition, eGlx restoration by the same means has the potential to treat other microvascular 
disorders where capillary leak to small solutes and large proteins is a key step in the progression 
of the disease.  
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10. Figure legends 
Figure 1. Transmission electron micrograph of the glomerular filtration barrier showing 
endothelial glycocalyx. Representative image from an FVB strain mouse, anaesthetised and 
perfusion fixed with Glutaraldehyde containing the cation, Alcian blue. This enabled 
visualisation of the electron dense, negatively charged glycocalyx on GEnCs. Of note, 
podocytes are also coated in glycocalyx. 
Figure 2. Hyaluronic acid and chondriotin sulphate expression in human glomeruli. Fresh 
frozen sectioned human glomeruli were treated with 250mg/ml HYAL (B), 100mU/ml 
chondroitinase (D), to show specificity, or left untreated (A and C). They were then fixed and 
immunostained with biotinylated hyaluronic acid binding protein (HABP) in conjunction with 
strepavidin-AF488(green) and anti-PECAM-1(red) (A and B), or anti-CS in conjunction with 
anti-mouse IgM AF488 (green) anti-PECAM-1(red) (C and D), and counterstained with DAPI 
(blue). Confocal Z stacks are shown. Architecture is not optimal in fresh frozen tissue and 
capillary loops are not apparent. Arrows indicate co-localisation of GAG with GEnCs, 
suggesting eGlx. 
Figure 3. VEGFC does not induce VEGFR2 phosphorlyation at tyrosine (ty) sites 1175, 1214 
or 951 in cultured glomerular endothelial cells (GEnC). GEnC were stimulated with 1nM 
VEGFA (VA), 10nM VEGFC (VC) or vehicle (Veh) for 2 min (A) or 30min (B). Cells were 
lysed and samples subjected to Western blotting for specific VEGFR2 tyrosine residues ty1175, 
ty1214 or ty951 and total VEGFR2. Representative blots are shown. Densitometry summary 
data is shown in C.  One-way ANOVA, Bonferroni post hoc tests indicated. *=p<0.05, 
***=p<0.001, n=3-6. 
Figure 4. The effect of protective paracrine growth factor signalling on restoration of eGlx in 
the glomerular filtration barrier. VEGF165 podocyte overexpression in early diabetic 
nephropathy leads to enhanced glomerular endothelial VEGFR2 activation, a damaged eGlx 
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and increased albuminuria (A). The overexpression of paracrine growth factors VEGF165b, 
Ang1 and VEGFC can impact the detrimental signalling of VEGF165 in a number of ways; 
podocyte VEGF165 expression or availability may be reduced; VEGFR2 signalling may be 
reduced/altered; enzymes associated with the synthesis, modification or shedding of GAG may 
be rebalanced such that the eGlx layer is restored and albuminuria is reduced. 
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